Post Content
Is HIMS a good stock to buy? We came across a bullish thesis on Hims & Hers Health, Inc. on Investment Ideas by Antonio’s Substack by Antonio Linares. In this article, we will summarize the bulls’ thesis on HIMS. Hims & Hers Health, Inc.’s share was trading at $29.76 as of April 21st. HIMS’s trailing and forward P/E were 60.80 and 72.99 respectively according to Yahoo Finance.
Hims & Hers Health, Inc. (Hims) is positioned as a vertically integrated digital healthcare platform transitioning from reactive treatment to preventive, data-driven medicine. The Q4 FY2025 update highlights early evidence of customers proactively engaging through diagnostics, lifting ARPU and reinforcing the shift toward preventative engagement rather than symptom-led care. Despite ongoing legal scrutiny and slowing subscriber growth, management indicates that the core weight loss exposure is limited and unlikely to materially affect the broader business model.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The investment thesis centers on a convergence between low-cost diagnostics and asymmetric peptide-based treatments, enabled by AI models trained on proprietary biomarker data. This creates a compounding flywheel where more diagnostics generate richer datasets, improving treatment recommendations, which in turn drives higher engagement and retention. Hims is moving healthcare from reactive prescribing to predictive prevention, where patients engage earlier through lab testing and identify risks before symptoms emerge.
Rising ARPU reflects deeper platform monetization as labs, hormonal therapies, and emerging verticals such as testosterone and menopause expand the subscription ecosystem. Valuation is viewed as disconnected from fundamentals, with market psychology underestimating the long-term value of a networked healthcare infrastructure.
International expansion, rising diagnostics penetration, and over $300 million in infrastructure investment position Hims for sustained scale-driven growth. Falling GLP-1 prices underscore a broader shift where value accrues not to molecules themselves but to data-driven selection of optimal therapies. This positions Hims as a potential category-defining subscription healthcare platform with expanding moat, strong long-term cash generation, and significant rerating potential as AI-driven preventive care scales globally.
Previously, we covered a bullish thesis on Hims & Hers Health, Inc. (HIMS) by Oliver | MMMT Wealth in May 2025, highlighting strong revenue growth, margin expansion and subscriber monetization. HIMS’s stock price has depreciated by approximately 43.15% since our coverage. Antonio Linares shares a similar view but emphasizes a preventive AI-driven diagnostics and biomarker personalization flywheel focus.